Compare Amgen, Inc. (AMGN) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Canopy Growth Corp — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Canopy Growth Corp trades at $0.97 (market cap $407.38M). The key difference: Amgen, Inc. is far larger — about 481.4× Canopy Growth Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| AMGN | CGC | |
|---|---|---|
Market Cap | $196.12B | $407.38M |
Sector | Health | Health |
52-Week High | $388.16 | $1.92 |
52-Week Low | $271.18 | $0.86 |
Enterprise Value | $241.41B | $346.82M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Canopy Growth (CGC) trades at $0.97, down 0.28% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses. Cash flow remains negative, but the balance sheet improved with a debt-to-asset ratio of 33.13% in 2025. Analyst sentiment is divided, with 33% buy ratings amid ongoing profitability challenges and potential reverse stock split discussions.
The outlook for CGC hinges on achieving profitability and navigating regulatory hurdles, with projected revenue growth to $285 million in 2026 offering a potential catalyst. Key risks include persistent losses, high debt, and Nasdaq compliance concerns, while institutional interest remains cautious. Investors should weigh the speculative turnaround potential against significant financial and operational headwinds in the volatile cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
